Mineralys Reports Q4/FY25 Results, Strong Cash Runway, but Lorundrostat Misses Primary Endpoint in OSA Trial

summarizeSummary

Mineralys Therapeutics reported its Q4 and full-year 2025 financial results, showing a strong cash position with runway into 2028, but announced that its lorundrostat candidate failed to meet the primary endpoint in a Phase 2 trial for obstructive sleep apnea.

check_boxKey Events

• Q4 and Full-Year 2025 Financial Results Announced

  Mineralys Therapeutics reported cash, cash equivalents, and investments of $656.6 million as of December 31, 2025, up from $198.2 million in 2024, providing a cash runway into 2028. The company also reported a reduced net loss of $154.7 million for the full year 2025, compared to $177.8 million in 2024.

• Lorundrostat Misses Primary Endpoint in OSA Phase 2 Trial

  The exploratory Phase 2 Explore-OSA trial for lorundrostat in obstructive sleep apnea (OSA) did not demonstrate a clinically meaningful difference relative to placebo on the primary endpoint, Apnea-Hypopnea Index (AHI). However, the trial did show a clinically meaningful reduction in blood pressure.

• FDA Accepts NDA for Lorundrostat in Hypertension

  The company reiterated the FDA's acceptance of its New Drug Application (NDA) for lorundrostat for the treatment of hypertension, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026. This follows the successful completion of five positive clinical trials.

auto_awesomeAnalysis

This 8-K provides a mixed update for Mineralys Therapeutics. On the positive side, the company reported a robust cash position of $656.6 million as of December 31, 2025, extending its operational runway into 2028, and a reduced net loss for 2025. It also reiterated the recent FDA acceptance of its New Drug Application for lorundrostat for hypertension, with a PDUFA date set for December 22, 2026. However, a significant negative is the announcement that lorundrostat failed to achieve its primary endpoint (Apnea-Hypopnea Index reduction) in the exploratory Phase 2 Explore-OSA trial for obstructive sleep apnea. While the trial did show a clinically meaningful reduction in blood pressure, the miss on the primary endpoint for OSA represents a setback for expanding lorundrostat's indications beyond hypertension. Investors should weigh the company's strong financial health and progress towards hypertension approval against the clinical disappointment in the OSA program.